Selecting appropriate therapy for lower-risk myelodysplastic syndromes: current state and future prospects

Farzad Teymouri,Constantin A. Dasanu
DOI: https://doi.org/10.1080/14656566.2024.2415714
2024-10-17
Expert Opinion on Pharmacotherapy
Abstract:KEYWORDS: Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal progenitor cell disorders, ranging from indolent to severe. [ Citation 1 ] All these entities are characterized by impaired hematopoiesis leading to various cytopenias, dysplastic cellular morphology, and variable risk of evolution to acute myeloid leukemia (AML) and bone marrow failure. [ Citation 2 ] MDS, a male predominant disease, has an annual incidence of 25 per 100,000 in individuals 65 years and older. [ Citation 3 ] Its etiopathogenesis is primarily driven by genetic mutations of myeloid stem cells that may occur de novo or secondary to environmental exposures such as various chemicals or ionizing radiation. [ Citation 2 , Citation 4 ] With the development of rapid availability of gene sequencing, diverse somatic mutation patterns have been detected in a majority of affected patients over the past few years. More than 100 genes have been found to be mutated in MDS, and these encode spliceosome components (SF3B1, U2AF1, SRSF2, EZH2), chromatin remodeling factors, epigenetic modifiers (TET2, DNMT3A, ASXL1), transcription factors (RUNX1, CEBPA, GATA2) and cell signaling genes (NRAS, KRAS, FLT3). These mutations tend to correlate with clinical phenotype, severity of cytopenias, blast percentage, cytogenetics and overall survival. [ Citation 2 , Citation 5 ]
pharmacology & pharmacy
What problem does this paper attempt to address?